---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-008045"
form_type: "8-K"
ticker: "DNA"
cik: "0001830214"
company_name: "Ginkgo Bioworks Holdings, Inc."
filed_at: "2024-02-29T23:59:59+00:00"
generated_at: "2026-06-05T07:18:35.003764+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ginkgo Bioworks FY2023 revenue $251M (-47% YoY); guides FY2024 total revenue $215-235M

## Summary
- Cell Engineering services revenue $139M (+31% YoY); added 78 new Cell Programs in 2023.
- Biosecurity revenue $108M (-68% YoY) as K-12 testing ramped down; shifting to recurring model.
- Q4 2023 total revenue $35M (-65% YoY); Q4 Adj. EBITDA loss $(96)M vs. $(76)M prior year.
- Cash balance $944M; FY2024 guidance: 100-120 new Cell Programs; total revenue $215-235M.
- Acquired Patch Biosciences, Proof Diagnostics, Reverie Labs; launched Technology Network of 25+ partners.

## SEC filing metadata
- accession: 0001628280-24-008045
- form_type: 8-K
- ticker: DNA
- cik: 0001830214
- company_name: Ginkgo Bioworks Holdings, Inc.
- filed_at: 2024-02-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1830214/000162828024008045/0001628280-24-008045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1830214/000162828024008045/dna-20240229.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-008045
- JSON: https://secwatch.observer/filing/0001628280-24-008045.json
- Plain text: https://secwatch.observer/filing/0001628280-24-008045.txt

## Key facts
- Earnings Releases
  Ginkgo Bioworks Holdings, Inc. reported financial results for fourth quarter 2023 and year ended December 31, 2023.
  - Period: fourth quarter 2023 and year ended December 31, 2023
  - Result: reported results
  source text: On February 29, 2024, Ginkgo Bioworks Holdings, Inc. issued a press release announcing its financial results for the fourth quarter 2023 and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1830214/000162828024008045/0001628280-24-008045-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.